Application : Formalin · HIER, Clone : MI15, Code Number : IR642, Immunogen : A mixture of U266 and XG-1 human myeloma cell lines (2, 8). See package insert for reference(s). Isotype : IgG1, kappa, Reagent Provided : Ready-to-use monoclonal mouse antibody provided in liquid form in a buffer containing stabilizing protein and 0.015 mol/L sodium azide. Solutions : Autostainer Link 48, Species : Mouse Anti-Human, Specificity : Anti-Human CD138, clone MI15, was clustered as anti-CD138 at the 6th International Workshop and Conference on Human Leuco ...
Multiple myeloma Other names Plasma cell myeloma, myelomatosis, Kahler's disease, myeloma [1] Bone marrow sample from a patient with multiple myeloma Specialty Hematology and oncology...
Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma. by Sabna Rajeev Krishnan, Frederick Luk, Ross D Brown, Hayley Suen, Yiulam Kwan, Mary Bebawy. Neoplasia...
Affiliation 1 DIACLONE Research, Besancon, France.
Isolate CD138+ plasma cells from bone marrow with the EasySep™ Human Bone Marrow CD138 Positive Selection Kit to enhance the sensitivity of validated diagnostic assays for multiple myeloma.
A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma
제품> 결과 필터링 ; 제품 상태별: Launched (6), 제품 유형별 : Protein (6), 종별: Human (6), 태그별: His Tag (3) · Fc Tag (1) · Fc Tag & Avi Tag (1) · His Tag & Avi Tag (1), 결합물별: Biotin-labeled (2) · FITC Labeled (1) · Unconjugated (2) · APC Labeled (1)
Request PDF | On Sep 12, 2019, Wen Shuai and others published CD138 − plasma cell myeloma | Find, read and cite all the research you need on ResearchGate
Abstract ; Multiple myeloma (MM) is a malignant disorder of the B cell lineage, characterized by neoplastic monoclonal expansion of plasma cells in the bone marrow resulting in destruction of adjacent bone tissue. MM remains an incurable disease (median overall survival, 4.4–7.1 y) despite the recent availability of new agents that, especially when used in combination regimens, have dramatically improved initial response rates (1–3). Therefore, new approaches that induce long-term tumor regression and improve disease outcome are needed and ...
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins 원문보기 Oncogenesis, v.5 no.2...